Skip to main content

Table 1 Demography and baseline characteristics (ITT population, N = 76)

From: Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study

  Mean (SD), N = 76
Age at informed consent, years 64.80 (8.39)
Height, cm 168.22 (8.55)
Weight, kg 75.45 (15.52)
BMI, kg/m2 26.65 (5.05)
Smoking history
Number of pack-years, years
50.13 (23.28)
Years since COPD diagnosis 5.17 (5.24)
Age at COPD diagnosis, years 60.16 (10.96)
FEV1 % predicted 56.09 (13.28)
FEV1*, L 1.50 (0.45)
FVC*, L 2.95 (0.89)
IC, L 2.45 (0.69)
Total Lung Capacity (TLC), L 7.13 (1.42)
TLC % of predicted normal value 120.68 (18.75)
Airway Resistance (Raw) 6.73 (3.19)
Raw % of predicted normal value 210.99 (117.11)
Hyperinflation IC/TLC 0.35 (0.09)
  N (%)
Gender Male 45 (59.2)
Female 31 (40.8)
Number of patients with current medical condition CAD 7 (9.2)
Hypertension 29 (38.2)
Diabetes mellitus 4 (5.3)
Number of patients according COPD GOLD-stage Stage I 8 (10.5)
Stage II 31 (40.8)
Stage III 30 (39.5)
Stage IV 7 (9.2)
  1. ITT intention to treat, N/n number of patients, BMI body mass index, SD standard deviation, COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, IC inspiratory capacity, CAD coronary artery disease, GOLD stage defined as: stage I = FEV1/FVC <70% and FEV1 ≥80% predicted; stage II = FEV1/FVC <70% and 50% ≤FEV1 <80% predicted; stage III = FEV1/FVC <70% and 30% ≤FEV1 <50% predicted; stage IV = FEV1/FVC <70% and FEV1 <30% predicted
  2. * N = 75
\